12 completed, 5 terminated, 3 recruiting, 2 active not recruiting. 10 Phase 3, 8 Phase 2, 6 Phase 1.
Follow Dexrazoxane Hydrochloride: new trials by email Literature Review of Dexrazoxane Hydrochloride trials Research Report on Dexrazoxane Hydrochloride
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations Allogeneic Hematopoietic Stem Cell Transplantation, Asparaginase Erwinia chrysanthemi, Biospecimen Collection - Acute Myeloid Leukemia | Phase 3 | Recruiting | Children's Oncology Group | 1400 | 2020-07-21 | 2026-09-17 |
| Dexrazoxane Hydrochloride in Preventing Heart-Related Side Effects of Chemotherapy in Participants With Blood Cancers Cladribine, Cytarabine, Dexrazoxane Hydrochloride - Acute Myeloid Leukemia, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 100 | 2018-09-19 | 2026-05-22 |
| Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL) Autologous Hematopoietic Stem Cell Transplantation, Biospecimen Collection, Bone Marrow Aspiration and Biopsy - Ganglioneuroblastoma, Ganglioneuroblastoma, Nodular | Phase 3 | Recruiting | Children's Oncology Group | 750 | 2018-05-14 | 2026-08-25 |
| Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Allogeneic Hematopoietic Stem Cell Transplantation, Calaspargase Pegol, Cyclophosphamide - Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia | Phase 3 | Active not recruiting | Children's Oncology Group | 352 | 2017-08-08 | 2026-10-05 |
| Crizotinib and Combination Chemotherapy in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma Crizotinib, Cyclophosphamide, Dexrazoxane Hydrochloride - Childhood Solid Neoplasm, Recurrent Childhood Anaplastic Large Cell Lymphoma | Phase 1 | Completed | Children's Oncology Group | 46 | 2013-04-29 | 2024-01-05 |
| Dexrazoxane as a Protective Agent in Anthracycline Treated Breast Cancer Dexrazoxane hydrochloride - Breast Cancer | Phase 2 | Terminated | Fudan University | 12 | 2009-06-01 | 2012-02-28 |
| Obatoclax Mesylate, Vincristine Sulfate, Doxorubicin Hydrochloride, and Dexrazoxane Hydrochloride in Treating Young Patients With Relapsed or Refractory Solid Tumors, Lymphoma, or Leukemia dexrazoxane hydrochloride, doxorubicin hydrochloride, obatoclax mesylate - Acute Leukemias of Ambiguous Lineage, Acute Undifferentiated Leukemia | Phase 1 | Terminated | National Cancer Institute (NCI) | 22 | 2009-06-01 | 2014-05-01 |
| Zoledronic Acid and Combination Chemotherapy in Treating Patients With Newly Diagnosed Metastatic Osteosarcoma cisplatin, dexrazoxane hydrochloride, doxorubicin hydrochloride - Sarcoma | Phase 1 | Completed | Children's Oncology Group | 24 | 2008-08-01 | 2014-07-04 |
| Combination Chemotherapy With or Without Topotecan in Treating Patients With Newly Diagnosed Localized Ewing's Sarcoma cyclophosphamide, dexrazoxane hydrochloride, doxorubicin hydrochloride - Sarcoma | Phase 3 | Withdrawn | Children's Oncology Group | 2005-12-01 | 2013-06-28 | |
| 05-001: Treatment of Acute Lymphoblastic Leukemia in Children asparaginase, cyclophosphamide, cytarabine - Drug/Agent Toxicity by Tissue/Organ, Leukemia | Phase 3 | Completed | Dana-Farber Cancer Institute | 800 | 2005-04-01 | 2026-07-30 |
| Chemoimmunotherapy With Epratuzumab in Relapsed Acute Lymphoblastic Leukemia (ALL) L-asparaginase, doxorubicin hydrochloride, therapeutic hydrocortisone - Recurrent Childhood Acute Lymphoblastic Leukemia | Phase 1 / Phase 2 | Completed | Children's Oncology Group | 134 | 2005-02-01 | 2017-12-12 |
| Irinotecan and Carboplatin as Upfront Window Therapy in Treating Patients With Newly Diagnosed Intermediate-Risk or High-Risk Rhabdomyosarcoma filgrastim, carboplatin, cyclophosphamide - Sarcoma | Phase 2 | Active not recruiting | Memorial Sloan Kettering Cancer Center | 65 | 2003-10-01 | 2026-05-22 |
| Chemotherapy Combined With Radiation Therapy for Newly Diagnosed CNS AT/RT filgrastim, cisplatin, cyclophosphamide - Central Nervous System Tumor, Pediatric | Phase 2 | Completed | Dana-Farber Cancer Institute | 25 | 2003-02-01 | 2015-12-24 |
| Oblimersen Plus Combination Chemotherapy and Dexrazoxane in Treating Children and Adolescents With Relapsed or Refractory Solid Tumors oblimersen sodium, dexrazoxane hydrochloride, doxorubicin hydrochloride - Cardiac Toxicity, Unspecified Childhood Solid Tumor, Protocol Specific | Phase 1 | Completed | National Cancer Institute (NCI) | 15 | 2002-11-01 | 2013-01-17 |
| Combination Chemotherapy and Dexrazoxane Followed by Surgery and Radiation Therapy in Treating Patients With Advanced Soft Tissue Sarcoma or Recurrent Bone Sarcoma filgrastim, dexrazoxane hydrochloride, doxorubicin hydrochloride - Sarcoma | Phase 2 | Terminated | City of Hope Medical Center | 7 | 2001-08-01 | 2014-08-28 |
| Combination Chemotherapy, Surgery, and Radiation Therapy With or Without Dexrazoxane and Trastuzumab in Treating Women With Stage III or Stage IV Breast Cancer dexrazoxane hydrochloride, doxorubicin hydrochloride, cyclophosphamide - Cardiac Toxicity, Inflammatory Breast Cancer | Phase 3 | Terminated | National Cancer Institute (NCI) | 396 | 2001-05-01 | 2013-01-16 |
| Dexrazoxane and Cisplatin in Treating Patients With Advanced Solid Tumors cisplatin, dexrazoxane hydrochloride, high performance liquid chromatography - Unspecified Adult Solid Tumor, Protocol Specific | Phase 1 | Completed | City of Hope Medical Center | 25 | 2001-02-01 | 2015-06-08 |
| Combination Chemotherapy Before and After Surgery in Treating Patients With Osteosarcoma filgrastim, cisplatin, dexrazoxane hydrochloride - Cardiac Toxicity, Sarcoma | Phase 2 | Terminated | National Cancer Institute (NCI) | 100 | 2000-03-01 | 2015-06-08 |
| Combination Chemotherapy Plus Dexrazoxane in Treating Patients With Newly Diagnosed Nonmetastatic Osteosarcoma cisplatin, dexrazoxane hydrochloride, doxorubicin hydrochloride - Cardiac Toxicity, Sarcoma | Phase 3 | Completed | Children's Oncology Group | 253 | 1999-09-01 | 2014-08-05 |
| Combination Chemotherapy and Biological Therapy in Treating Patients With High-Risk Ewing's Sarcoma cyclophosphamide, dexrazoxane hydrochloride, disaccharide tripeptide glycerol dipalmitoyl - Sarcoma | Phase 2 | Completed | Memorial Sloan Kettering Cancer Center | 1998-09-01 | 2013-06-25 |
Showing 20 of 23. Sign in to see all of them.
Cardiotoxicity (7) · Sarcoma (7) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (4) · Lymphoma (3) · Neuroectodermal Tumors, Primitive, Peripheral (3) · Osteosarcoma (3) · Blast Crisis (2) · Breast Neoplasms (2) · Burkitt Lymphoma (2) · Leukemia (2) · Leukemia, Biphenotypic, Acute (2) · Leukemia, Myeloid, Acute (2) · Lymphoma, Large-Cell, Anaplastic (2) · Neuroblastoma (2) · Central Nervous System Neoplasms (1)
Children's Oncology Group (11) · National Cancer Institute (NCI) (4) · City of Hope Medical Center (2) · Dana-Farber Cancer Institute (2) · Memorial Sloan Kettering Cancer Center (2) · Fudan University (1) · M.D. Anderson Cancer Center (1)
United States (18) · Canada (11) · Australia (6) · Puerto Rico (6) · Switzerland (3) · Netherlands (2) · Austria (1) · Belgium (1) · Chile (1) · China (1) · Czechia (1) · Finland (1) · France (1) · Germany (1) · Hong Kong (1)
Cindy Schwartz, MD (2) · Andrea Biondi (1) · Barbara L. Asselin, MD (1) · Cameron K. Tebbi, MD (1) · Elizabeth Raetz, MD (1) · Emily Greengard (1) · Leo Mascarenhas, MD (1) · Leonard H. Wexler, MD (1) · Lewis B Silverman (1) · Lynda Vrooman, MD (1) · Mark Graham (1) · Mark W. Kieran, MD, PhD (1) · Maro Ohanian (1) · Mason Bond, MD (1) · Michael A. Weiner, MD (1)
PMID 19064966, PMID 19584400, PMID 20007809, PMID 22689804, PMID 22911615, PMID 23393050, PMID 23664013, PMID 26549586, PMID 29090520, PMID 29941458, PMID 32154021, PMID 33095287, PMID 33843815, PMID 34028986, PMID 38107263, PMID 38947228, PMID 41920422, PMID 42497367
U10CA180886 (3), P30CA006516 (2), P30CA033572 (2), U01CA097452 (2), 2017 (1), P01CA068484 (1), P30CA016672 (1), U10CA030969 (1), U10CA031946 (1), U10CA098543 (1), UM1CA097452 (1)